Stock market analyst Ramesh Arora has maintained 'hold' rating on Ankur Drugs & Pharma Ltd stock.

According to analyst, the interested investors can buy the stock with strict stop loss of Rs 111.

Mr. Arora added that the stock will show upmove on crossing its resistance of Rs 148-150.

The stock of the company, on Sep 01, marked its closure at Rs 135.10 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 251and a low of Rs 116 on BSE.

Ankur Drugs And Pharma Ltd is an Indian pharmaceutical company, which is involved in contract manufacturing of pharmaceuticals formulations of a variety of dosage forms to global pharmas.

The business section of Ankur Drugs And Pharma Ltd consists of pharmaceutical formulations in the form of tabs, liquid orals, caps, oral powder, dry syrups, balms both fabricated and outsourced.

The Company's customers comprise, Cipla Ltd, Blue cross Labs Ltd, Khandelwal Laboratories Pvt. Ltd, Ranbaxy Lab Ltd Lyka Labs Ltd, Wockhardt Ltd, Synthiko Formulations, Glenmark Pharma Ltd, Hetero Healthcare Ltd, Elder Pharma Ltd, Makers Laboratories Ltd, Cadila Laboratories Ltd, Parentral Drugs (India) Ltd, Torrent Pharmaceuticals Ltd, Sandoz (India) Pvt Ltd, Shreya Life Sicences Pvt. Ltd and Nicholas Piramal India Ltd.